First amendment to the Aetna Life Insurance Company agreement for medical and pharmacy benefit administration

Two of five models read this as partial, two as bad and one as missing, so no verdict had a majority; under the median rule the middle vote falls in the bad or missing tier, and a re-read of pages 10, 12 and 47 shows the text is not silent, so the verdict is bad. The only fiduciary language is section 9.4 of the Medicare Group Agreement (page 12), which makes Aetna a fiduciary solely for ERISA claim determinations and pairs that with complete authority to construe the agreement under a deferential arbitrary and capricious standard. Section 7.1 (page 10) frames the parties as independent contractors, and page 47 has the county agree that manufacturer payments belong exclusively to Aetna or CVS Caremark with no legal interest for the county. Nothing extends a duty of loyalty or care to formulary, network or pricing decisions, and the base agreement that might hold one is not in the file. Claude Opus 5 and GPT 5.6 Sol treated the narrow ERISA clause as a weaker version of the model duty; Gemini 3.1 Pro called it missing because the base agreement is absent.

Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing

Four of five models read this as partial; Gemini 3.1 Pro called it missing because the base agreement is not in the file. The Other Payments section (pages 46 and 47) does tell the county, by category, that manufacturer administrative fees, data and education payments, network transmission fees, medical benefit specialty rebates and value based contracting payments are kept by Aetna or CVS Caremark, and page 72 notes the rates exclude commissions. That is disclosure of conflicts by category, not a full accounting of amounts, and no named officer certifies quarterly or annually that everything has been disclosed and remitted. Producer compensation information on page 85 is available only if the county asks.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing

Four of five models read this as partial; Gemini 3.1 Pro called it missing because there is no ownership exhibit. The file does name the corporate family in narrative form: CVS is the parent of Aetna and SilverScript (pages 31 and 72), CaremarkPCS Health and its affiliates are the pharmacy benefit manager (page 36), mail order is CVS Caremark Mail Service Pharmacy (page 31) and specialty is CVS Specialty (page 40). There is no signed exhibit listing every owner, subsidiary, group purchasing organization, rebate aggregator and affiliated pharmacy, and no duty to refresh the list within 30 days of a change in control, which is what the exhibit proposed alongside the model contract from Mark Cuban and collaborators requires.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing

Four of five models read this as bad; Gemini 3.1 Pro called it missing because the controlling definition sits in the Prescription Drug Services Schedule, which is not attached. The text that is present defines rebates by subtraction: manufacturer administrative fees, other manufacturer payments for data and education, and network transmission fees are each carved out of Rebates (page 46), and page 38 says capitalized terms in the pricing charts are not defined terms except where the missing schedule says so. Specialty is defined by the Aetna Specialty Product List (page 36), a vendor label rather than an economic function. This is the relabeling loophole the definitions article of the model contract exists to close, and the county agreed to exclusions from a definition it cannot read in this file.

Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro missing

Four of five models read this as bad; Kimi K3 read it as partial because the rebate table promises the greater of 100 percent or a per brand script minimum. The rebate terms on page 37 do state minimum guarantees, but the 100 percent applies only to Rebates as narrowly defined, and pages 46 and 47 exclude administrative fees, data and education payments, network transmission fees, medical benefit specialty rebates and value based contracting payments, then have the county disclaim any legal interest in those amounts. Rebates are paid 180 days after the quarter ends (page 45) rather than within 30 days, and the guarantee excludes long lists of claims (page 41). One hundred percent of a shrunken definition, paid six months late, is not the full pass through of manufacturer revenue the model contract requires.

Model votes: Kimi K3 partial, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro bad

Four of five models read this as bad; Gemini 3.1 Pro called it missing because no acquisition cost clause exists in the file. Mail order is filled by CVS Caremark Mail Service Pharmacy (page 31) and specialty must be filled at CVS Specialty pharmacies with no retail fills (page 40), so the affiliated channels carry most of the spend. Those channels are priced as discounts off average wholesale price, for example mail brand at AWP minus 19.50 percent and specialty at AWP minus 22.75 percent in 2026 (page 36), under a traditional pricing arrangement that lets Aetna keep the difference between what the county pays and what the pharmacy receives (page 44). Nothing prices an affiliate claim at net acquisition cost plus a stated dispensing fee, and there is no documentation default if cost records are not produced.

Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro missing

Three of five models read this as partial; Grok 4.6 and Kimi K3 called it missing because the lesser of language on page 39 protects only the member at the counter, not what the plan is charged. The Caremark Cost Saver footnote on page 57 does compare the Aetna network price with a non Aetna network price claim by claim and routes the claim to the cheaper one, and page 39 gives the member the lesser of usual and customary, MAC or discounted AWP. Neither is a ceiling tied to a published benchmark such as a transparent cash price, neither covers every drug and channel, and Aetna reserves the right to re-evaluate pricing when its assumptions change (page 40). The protection is real but narrow, which is why partial stands with modest confidence.

Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

Four of five models read this as partial; Kimi K3 called it missing because the lesser of clause is a pharmacy pricing term rather than a member right. At a participating pharmacy the member pays the lesser of the cost share, the pharmacy usual and customary charge, MAC or the discounted AWP price (page 39), which stops the member from paying more through the plan than the pharmacy cash price at that counter. Nothing lets a member fill outside the plan at a lower cash price and have it count toward the deductible or out of pocket maximum, and the PrudentRx guarantee on page 43 assumes a true accumulation plan design without any written election by the county. The model clause from Mark Cuban and collaborators covers both halves; this text covers one.

Model votes: Kimi K3 missing, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

Two of five models read this as partial, two as missing and one as bad, so no verdict had a majority; the median falls in the bad or missing tier, and the rule for that tie is to re-read the pages the bad voter cited and ask whether the text permits the harm or is merely silent. It permits it. MAC pricing applies at mail order (page 39) and dozens of specialty generics on pages 59 to 71 are priced at MAC, yet the county is on a traditional or lock in arrangement under which the amount charged to the county for a network claim may differ from the amount paid to the pharmacy and Aetna keeps the difference (pages 43 and 44). That is a contractual license for one price list on the county side and another on the pharmacy side, which is the two list harm the model MAC clause exists to prevent. No MAC list is disclosed, no update schedule is set and no pharmacy appeal path with timelines appears; Claude Opus 5 and GPT 5.6 Sol treated the passing references as a weak form of governance, and Gemini 3.1 Pro and Kimi K3 read the same passages as silence. Confidence is low because only Grok 4.6 reached this verdict directly.

Model votes: Kimi K3 missing, Grok 4.6 bad, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing

All five models reached this verdict. The Additional Disclosures section has the county acknowledge that the discounts and dispensing fees reflect a Traditional or Lock-In pricing arrangement (page 43) and then defines that arrangement as one where the amount charged to the county and its members may differ from the amount paid to the pharmacy, with Aetna keeping the difference on top of its other fees (page 44). That is spread pricing stated in writing. A Traditional Pricing Auxiliary Fee of $1.50 per retail claim applies in states whose laws require transparent pricing (page 52), so where the spread is forbidden a fee takes its place.

Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro bad

Three of five models read this as bad; Gemini 3.1 Pro and Kimi K3 called it missing because no group purchasing organization or rebate aggregator is named anywhere in the file. The text never uses those words, but it does describe the money such entities collect: payments from drug manufacturers and other organizations for data and education (page 46), network transmission fees from pharmacies (page 46), and on page 47 the county agrees these amounts are earned across the Aetna book of business and belong exclusively to Aetna or its affiliate CVS Caremark. Nothing requires purchase discounts, volume credits or supplier payments received by any related purchasing entity to flow to the plan. The majority read that as affirmatively permitting the leakage rather than staying silent about it.

Model votes: Kimi K3 missing, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro missing

All five models reached this verdict. The Formulary Management section (page 46) gives the county sole discretion to accept or reject the formulary, but only from options Aetna decides to offer, and Aetna may propose changes based on market conditions, clinical information, cost, rebates and other factors. Pricing and rebate guarantees are conditioned on the Aetna Standard Formulary, the Choose Generics program and the Advanced Control Specialty Formulary (pages 40 and 41), and a custom formulary with net cost analysis is a priced extra at $100,000 (page 53). There is no requirement that the county approve every change, receive lowest net cost analysis or get utilization management outcomes by drug each quarter.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

All five models reached this verdict. The formulary section on page 46, the rebate terms on pages 41 and 42, the market check on page 43 and the additional services list on pages 53 to 57 were all searched. Page 46 names cost and rebates among the reasons Aetna may propose formulary changes but sets no lowest net cost standard for this plan, and net cost analysis appears only as a feature of the $100,000 custom formulary service on page 53. No annual comparison against the Aetna book of business is promised, and the base agreement that might hold such a standard is not in the file.

No verbatim quote is available for this clause.

Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing

Four of five models read this as bad; Gemini 3.1 Pro called it missing because the base agreement is not in the file. Page 40 requires members to use CVS Specialty pharmacies with no retail fills, conditions the specialty discount on Aetna being the exclusive specialty provider except for the HIV class, and lets Aetna amend pricing if retail leakage rises 10 percent or more. Mail order is likewise routed to CVS Caremark Mail Service Pharmacy (page 31) and the P1 preferred network charges members more at standard pharmacies (page 31). That is steering into pharmacies owned by the vendor's parent, with no any willing pharmacy right, no bar on retroactive clawbacks and no protection for independent pharmacies.

Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro missing

All five models reached this verdict. The Market Check section (page 43) allows an annual review in the second quarter of each contract year, by Aetna and the county or a mutually agreed third party under a non-disclosure agreement, against offers made to similar employers. If the review shows savings of 2 percent or more in net costs the only remedy is a good faith discussion, and any agreed change takes effect the following January 1. There is no automatic most favored pricing promise and no meet, credit or release right, so the clause is real but weaker than the model.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

All five models reached this verdict. Pharmacy Audit Rights and Limitations (page 48) grants one rebate audit and one electronic claim audit a year, at the county's own expense unless otherwise agreed, and both are subject to audit terms in the Prescription Drug Services Schedule, which is not in the file. Audit claim files for data over 24 months old cost $5,000 per file and historical claims data costs $1,000 per file (page 54). There is no right to full claims level and financial data on a schedule without asking, no pre-adjudication access and no statement that nothing will be withheld as proprietary.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

Three of five models read this as bad; Gemini 3.1 Pro and Grok 4.6 called it missing because no clause states who owns the data either way. The majority pointed to the Vendor Transition Files table (page 54), which charges the county per file for its own accumulator files, historical claims data, precertification history and refill transfers at termination, and to page 46, where Aetna is paid by manufacturers for the analysis or provision of aggregated data. Nothing in the file says the county owns its claims, eligibility, accumulator or rebate data, that it is delivered in machine readable form on request, or that Aetna may not reuse or sell it. Pricing a public body's access to its own records is the switching barrier the model clause exists to prevent, which is why the majority read the text as permitting the harm rather than staying silent.

Model votes: Kimi K3 bad, Grok 4.6 missing, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro missing

Three of five models read this as partial; GPT 5.6 Sol read it as bad because the PrudentRx remedy is a capped credit, and Gemini 3.1 Pro called it missing because the base agreement is absent. Discount, dispensing fee and rebate guarantees do exist and are reconciled, and page 39 keeps discount and dispensing fee components from offsetting each other. The rebate side is weaker: components are reconciled in the aggregate up to 12 months after the plan year (page 42), discount reconciliation can take 180 days (page 39), and the PrudentRx savings guarantee pays out as a credit against future billing capped at 30 percent of the program cost (page 43). Guarantees measured annually with offsets and capped credits are weaker than the quarterly, dollar for dollar cash remedies in the model.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol bad, Claude Opus 5 partial, Gemini 3.1 Pro missing

Three of five models read this as missing; Claude Opus 5 and GPT 5.6 Sol read it as partial because the PrudentRx credit on page 43 pays without the county proving damages. The guarantee reconciliations on pages 39 to 43 are performance true ups on specific programs, not a general rule that missed guarantees or late reports trigger liquidated damages or automatic credits. The termination article of the Medicare Group Agreement on pages 8 and 9 has no two strikes or repeat breach exit, and the only self executing remedies in the file run against the county: 12.0 percent annual late payment interest (page 48) and the Early Termination Fee (page 47). A general enforcement clause would live in the base agreement, which is not in the file.

No verbatim quote is available for this clause.

Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing

All five models reached this verdict. Section 9.17 of the Medicare Group Agreement (page 14) lists three ways to amend: automatically to conform with regulatory mandates, by mutual written agreement, or by Aetna alone on 30 days written notice, and adds that all amendments must be approved and executed by Aetna. The pharmacy schedule adds further one sided rights: Aetna may amend individual specialty drug discounts to manage its guarantee (page 40) and may make an Equitable Adjustment to the financial provisions on stated triggers, some effective 30 days after notice (page 44). The model contract allows changes only when both parties sign.

Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro bad

All five models reached this verdict. Section 5.1 of the Medicare Group Agreement lets either party terminate without cause on 90 days notice (page 8), but the pharmacy schedule takes the value back: if the county ends pharmacy services before December 31, 2028, Aetna keeps earned but unpaid rebates, the year's pharmacy guarantees become null and void and are not reconciled, and the county must refund prorated allowances, all labeled liquidated damages and an Early Termination Fee due within 60 days (page 47). Forfeiting earned money on exit is the trap the model termination clause exists to remove.

Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro bad

Three of five models read this as bad; Claude Opus 5 and Gemini 3.1 Pro read it as partial because the drug level discount table on pages 59 to 71 is unusually detailed. Specialty is defined by the Aetna Specialty Product List (page 36), a vendor label rather than an economic function, and members must use CVS Specialty pharmacies with Aetna as exclusive provider except for HIV drugs (page 40). Pricing is a blended AWP minus 22.75 percent guarantee in 2026 (page 36) with drug level rates that Aetna may amend to manage its own guarantee, new to market products at AWP minus 16.00 percent and a default rate of 17.00 percent (pages 40 and 71). Drug level rates that the vendor can move are not a ceiling, and nothing prices affiliate specialty claims at acquisition cost, so the majority read the text as contradicting the model rather than weakening it.

Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 partial, Gemini 3.1 Pro partial

All five models reached this verdict. The Financial Conditions document (page 27) bars Harris County from releasing the pricing proposal to any third party without Aetna's written consent, and section 9.20 of the Medicare Group Agreement (page 14) sweeps the agreement itself and costs and pricing data into Confidential Information that may not be disclosed without consent. The Public Records Acts clause (page 22) acknowledges the county is subject to disclosure law but requires notice to Aetna, time to claim exemptions, a promise not to oppose Aetna's court action to block release, and disclosure of only the minimum a court orders. Every pricing exhibit carries a not for further distribution legend. That combination treats what taxpayers pay as the vendor's secret, so the red flag is set.

Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro bad